NanoViricides, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
25.5M
on 2026-09-28, from 11.8M on 2024-03-31 10-K ↗
a raise that quarter, at its price
$4.0M
Agreement of 2026-07-17. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
No warrant count read from a 10-Q or 10-K.
Cash
1.5 quarters
$2.8M on 2026-06-30 ÷ $1.9M a quarter of operating cash used, the average of four quarters. 10-K ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-07-27 | Public offering | not read | $1.86 | not read | 424B5 ↗ |
| 2026-07-27 | Registered direct offering incl. 0.10M pre-funded | 2,516,339 | $1.53 | $3.8M | 424B5 ↗ |
| 2026-05-18 | Registered direct offering incl. 0.20M pre-funded | 1,333,334 | $1.50 | $2.0M | 424B5 ↗ |
| 2025-11-12 | Public offering | not read | $2.00 | not read | 424B5 ↗ |
| 2025-11-10 | Registered direct offering incl. 1.60M pre-funded | 3,571,429 | $1.68 | $6.0M | 424B5 ↗ |
Also on file: a going-concern note in the 10-K filed 2026-09-28 10-K ↗